Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine
Florence Vorspan, Peter Hjelmström, Nicolas Simon, et al.
Expert Opinion on Drug Delivery (2019) Vol. 16, Iss. 9, pp. 907-914
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence
Kari Lancaster, Sandra Gendera, Carla Treloar, et al.
International Journal of Drug Policy (2024) Vol. 126, pp. 104359-104359
Open Access | Times Cited: 6
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
Adrian Dunlop, Bethany White, Jillian Roberts, et al.
Addiction (2021) Vol. 117, Iss. 2, pp. 382-391
Open Access | Times Cited: 34
The innovation of long-acting injectable buprenorphine in the management of opioid use disorder in prisons: A manifesto shared by experts with delphi panel survey
Sarah Vecchio, Carmelo Cantone, Felice Nava, et al.
Heroin addiction and related clinical problems (2025) Vol. 27, Iss. 1, pp. 1-11
Closed Access
Prolonged-release buprenorphine formulations: Perspectives for clinical practice
Mathieu Chappuy, Benoît Trojak, Philippe Nubukpo, et al.
Therapies (2020) Vol. 75, Iss. 5, pp. 397-406
Open Access | Times Cited: 34
Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries
Benjamin Rolland, Catriona Matheson, Ari Kaski, et al.
Expert Opinion on Drug Delivery (2024) Vol. 21, Iss. 5, pp. 809-815
Open Access | Times Cited: 4
Long-acting depot buprenorphine in people who are homeless: Views and experiences
Catriona Matheson, Rebecca Foster, Joe Schofield, et al.
Journal of Substance Abuse Treatment (2022) Vol. 139, pp. 108781-108781
Open Access | Times Cited: 17
Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review
Cayley Russell, Tony P. George, Nitin Chopra, et al.
The American Journal of Drug and Alcohol Abuse (2024) Vol. 50, Iss. 5, pp. 567-586
Open Access | Times Cited: 3
Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
Cayley Russell, Frishta Nafeh, Michelle Pang, et al.
BMC Public Health (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update
Michael B. Soyka
Pharmacopsychiatry (2020) Vol. 54, Iss. 01, pp. 18-22
Closed Access | Times Cited: 18
Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
Cayley Russell, Michelle Pang, Frishta Nafeh, et al.
International Journal of Qualitative Studies on Health and Well-Being (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone
Benjamin Rolland, Benoît Trojak, Mikaïl Nourredine, et al.
Drug and Alcohol Dependence (2021) Vol. 220, pp. 108492-108492
Open Access | Times Cited: 15
Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
Michael Soyka, Andreas G. Franke
World Journal of Psychiatry (2021) Vol. 11, Iss. 9, pp. 543-552
Open Access | Times Cited: 11
Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder
Stephen Parkin, Joanne Neale, John Strang
Substance Use & Misuse (2023) Vol. 58, Iss. 13, pp. 1696-1706
Open Access | Times Cited: 4
Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose
Grant Victor, Katie Bailey, Bradley Ray
Substance Use & Misuse (2021) Vol. 56, Iss. 7, pp. 988-996
Closed Access | Times Cited: 10
Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study
Joseph Tay Wee Teck, Alex Baldacchino, Lauren Gibson, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 10
How to be self-reliant in a stigmatising context? Challenges facing people who inject drugs in Vietnam
Nguyễn Thu Trang, Marie Jauffret‐Roustide, Lê Minh Giang, et al.
International Journal of Drug Policy (2020) Vol. 87, pp. 102913-102913
Open Access | Times Cited: 10
<p>OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis</p>
Nat Wright, Jake Hard, Colin Fearns, et al.
ClinicoEconomics and Outcomes Research (2020) Vol. Volume 12, pp. 499-504
Open Access | Times Cited: 10
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
Mathieu Chappuy, Fadi Meroueh, Benoît Trojak, et al.
Patient Preference and Adherence (2021) Vol. Volume 15, pp. 1259-1267
Open Access | Times Cited: 8
Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross‐sectional study in three Australian cities
Suzanne Nielsen, Paul G. Sanfilippo, Vendula Běláčková, et al.
Addiction (2020) Vol. 116, Iss. 6, pp. 1482-1494
Closed Access | Times Cited: 6
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Francisco Salvador Pascual, Álvaro Muñoz, Rodrigo Oraá, et al.
European Addiction Research (2021) Vol. 28, Iss. 2, pp. 143-154
Open Access | Times Cited: 6
Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN)
Louise Carton, Mikaïl Nourredine, Benjamin Rolland
Therapies (2020) Vol. 76, Iss. 2, pp. 127-136
Closed Access | Times Cited: 5
Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: a retrospective cross-sectional study
Alice Deschenau, Benoît Trojak, Georges Brousse, et al.
Therapies (2024)
Open Access
The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients
Stephanie Paula Elisabeth Guillery, Sven Reiners, Marius Fahrner, et al.
Addiction Biology (2023) Vol. 28, Iss. 5
Open Access | Times Cited: 1
Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence
Bernadette Hard
Case Reports in Psychiatry (2021) Vol. 2021, pp. 1-3
Open Access | Times Cited: 3
Buprénorphine d’action prolongée : quelles perspectives pour la pratique clinique ?
Mathieu Chappuy, Benoît Trojak, Philippe Nubukpo, et al.
Therapies (2020)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top